Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 14/20 | 0.42 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.39 |
| ▸ | C5 | P01031 | 2/20 | 0.38 |
| ▸ | TNF | P01375 | 1/20 | 0.38 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.38 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | KCNJ6 | P48051 | 1/20 | 0.38 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.38 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19377140 | 0.84 | ROCK2 (0.46) | C5 | |
| SCHEMBL19377377 | 0.82 | ITGB3 (0.46) | C5 | |
| SCHEMBL19377279 | 0.80 | HTR1A (0.43) | ACACBABCB1TNFNOD2NOD1 | |
| SCHEMBL19377277 | 0.78 | ACACB (0.44) | ACACBABCB1TNFNOD2NOD1 | |
| SCHEMBL19377382 | 0.77 | HSD17B10 (0.43) | C5 | |
| SCHEMBL19377137 | 0.76 | ROCK2 (0.46) | C5 | |
| SCHEMBL19377374 | 0.75 | ITGB3 (0.46) | C5 | |
| SCHEMBL24800223 | 0.73 | ITGB3 (0.38) | — | |
| SCHEMBL19377412 | 0.71 | HSD17B10 (0.46) | ACACBABCB1 | |
| SCHEMBL19377385 | 0.69 | HSD17B10 (0.43) | C5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170275301-A1 | Benzenesulfonyl-Asymmetric Ureas and Medical Uses Thereof | HELSINN HEALTHCARE SA (CH) | 2017-09-28 | — | — | US | disclosed |
| US-20170275301-A1 | Benzenesulfonyl-Asymmetric Ureas and Medical Uses Thereof | HELSINN HEALTHCARE SA (CH) | 2017-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170275301-A1 | Benzenesulfonyl-Asymmetric Ureas and Medical Uses Thereof | UTS2R, GHSR, GRPR | ACACB 2049/4885ABCB1 1573/4885C5 4885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.